Benjamin Landry Sells 2,500 Shares of Health Catalyst, Inc. (NASDAQ:HCAT) Stock

Health Catalyst, Inc. (NASDAQ:HCAT) General Counsel Benjamin Landry sold 2,500 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $7.52, for a total value of $18,800.00. Following the completion of the sale, the general counsel now directly owns 72,250 shares of the company’s stock, valued at approximately $543,320. This trade represents a 3.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Benjamin Landry also recently made the following trade(s):

• On Friday, December 6th, Benjamin Landry sold 19,268 shares of Health Catalyst stock. The shares were sold at an average price of $8.32, for a total value of $160,309.76.

Health Catalyst Stock Down 6.4 %

Health Catalyst stock opened at $6.89 on Friday. The stock’s 50 day moving average price is $7.79 and its 200 day moving average price is $7.53. The company has a market cap of $419.24 million, a PE ratio of -5.10 and a beta of 1.36. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. Health Catalyst, Inc. has a 1-year low of $5.42 and a 1-year high of $11.41.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The company had revenue of $76.40 million for the quarter, compared to analyst estimates of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The business’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same period last year, the company earned ($0.22) earnings per share. On average, sell-side analysts predict that Health Catalyst, Inc. will post -0.33 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. KeyCorp raised shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 target price on the stock in a report on Wednesday. Piper Sandler reaffirmed an “overweight” rating and issued a $12.00 target price (up from $11.00) on shares of Health Catalyst in a report on Tuesday, November 26th. Citigroup lowered their price target on Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a report on Friday. Stephens increased their price objective on Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a research report on Thursday, November 14th. Finally, Royal Bank of Canada boosted their target price on Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a report on Thursday, November 7th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.45.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. increased its stake in Health Catalyst by 6.9% in the 2nd quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock valued at $188,000 after purchasing an additional 1,907 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Health Catalyst by 9.1% during the 2nd quarter. Rhumbline Advisers now owns 91,111 shares of the company’s stock worth $582,000 after buying an additional 7,589 shares during the last quarter. Los Angeles Capital Management LLC boosted its position in shares of Health Catalyst by 276.3% in the 2nd quarter. Los Angeles Capital Management LLC now owns 213,693 shares of the company’s stock worth $1,365,000 after buying an additional 156,908 shares in the last quarter. Acadian Asset Management LLC grew its stake in Health Catalyst by 1.3% in the 2nd quarter. Acadian Asset Management LLC now owns 734,257 shares of the company’s stock valued at $4,690,000 after acquiring an additional 9,697 shares during the last quarter. Finally, ClariVest Asset Management LLC increased its holdings in Health Catalyst by 1.2% during the 2nd quarter. ClariVest Asset Management LLC now owns 285,627 shares of the company’s stock valued at $1,825,000 after acquiring an additional 3,302 shares in the last quarter. 85.00% of the stock is owned by hedge funds and other institutional investors.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.